Original Article
Megestrol Acetate for the Prevention of Hot Flashes
N Engl J Med 1994; 331:347-352August 11, 1994
- Abstract
Background
Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of patients.
Methods
The patients included 97 women with a history of breast cancer and 66 men with prostate cancer who had undergone androgen-deprivation therapy. All patients had experienced bothersome hot flashes (median number per day at base line, 6.1 for the women and 8.4 for the men). After a one-week pretreatment observation period, the patients received megestrol acetate (20 mg twice daily) for four weeks, followed by placebo for four weeks, or vice versa in a double-blind manner as determined by pretreatment randomization. The patients documented the frequency and severity of hot flashes in daily symptom diaries.
Results
After four weeks, hot flashes were reduced by 21 percent in the group receiving placebo first and by 85 percent in the group receiving megestrol acetate first (P<0.001). An intention-to-treat analysis of data for all eligible treated patients showed that 74 percent of the megestrol acetate group, as compared with 20 percent of the placebo group, had a decrease of 50 percent or more in the frequency of hot flashes during the first four weeks (P<0.001). The degree of efficacy was similar in men and women. The only side effect was withdrawal menstrual bleeding in women, generally occurring one to two weeks after the megestrol acetate had been discontinued.
Conclusions
Low-dose megestrol acetate is well tolerated and can substantially decrease the frequency of hot flashes in women and men. .
Media in This Article
Figure 1
Mean Hot-Flash Scores for Women (Panel A) and Men (Panel B) Receiving Megestrol Acetate or Placebo.Figure 2
Mean Hot-Flash Scores for Women during the Base-Line Week, the Two Four-Week Crossover Periods, and the Four-Week Period of Open-Label Megestrol Acetate.Article Activity
- Article
Vasomotor hot flashes occur commonly in menopausal women. In addition, they are the most frequent side effect associated with the antiestrogen drug tamoxifen1. The cause of vasomotor symptoms is not entirely understood. Casper and Yen2 have hypothesized that throughout reproductive life physiologic levels of estrogen and progesterone maintain endogenous opioid peptide concentrations in the hypothalamus and brain stem. Declining estrogen levels at the time of menopause result in decreased endogenous peptide activity, with the release of noradrenergic activity from its usual inhibition. This noradrenergic hyperactivity leads to inappropriate activation of heat-loss mechanisms in the medial preoptic area. Hot flashes, which appear to coincide with increased concentrations of gonadotropin-releasing hormone, are the result.
The most common treatment for hot flashes in women is estrogen-replacement therapy, which may eliminate hot flashes altogether. However, many physicians believe that estrogen-replacement therapy is relatively contraindicated in patients with breast cancer because of the concern that it may stimulate growth of the tumor.
Men who have undergone androgen-deprivation therapy (bilateral orchiectomy or treatment with a gonadotropin-releasing-hormone agonist) for metastatic prostate cancer also may have hot flashes3-8. Such symptoms can interfere with the quality of life3.
Preliminary data have suggested that megestrol acetate, a progestational agent, can decrease the frequency of hot flashes. A nonblinded study reported that megestrol acetate in daily doses of 20, 40, and 80 mg decreased menopausal hot flashes by 80, 89, and 98 percent, respectively9. Beneficial effects of other progestational agents on menopausal hot flashes have also been reported10-14. A pilot study reported that low doses of a progestational hormone abolished hot flashes in five of seven men (71 percent) who had undergone orchiectomy3.
Our trial was designed to assess the efficacy and short-term toxicity of low-dose megestrol acetate as a treatment for hot flashes in women with breast cancer and in men who had undergone androgen-deprivation therapy for prostate cancer.
Methods
Patient Population
The patients were either women with a history of breast cancer or men who had undergone a surgical bilateral orchiectomy or a so-called medical orchiectomy with the use of a gonadotropin-releasing-hormone agonist. To be eligible for the study, the patients must have had bothersome hot flashes for at least one month. Bothersome hot flashes were defined as hot flashes that occurred at least seven times per week and were sufficiently severe that the patient desired therapeutic intervention. All patients had a life expectancy of six months or more. Current or planned therapy with antineoplastic chemotherapy, androgens, estrogens, progestational agents, or corticosteroids was not allowed. However, the antiestrogen agent tamoxifen (20 mg per day) was permitted. Women who were breast-feeding and those with childbearing potential were excluded from the study.
Study Design
Informed consent was obtained from all the patients, as directed by federal guidelines. All the patients were stratified according to the duration of hot flashes (less than nine months, or nine or more months) and the average daily frequency of hot flashes (1 to 3, 4 to 9, or 10 or more). In addition, the men were stratified according to the type of orchiectomy they had undergone (medical or surgical) and the duration of androgen ablation (less than 4 months, 4 to 12 months, or more than 12 months), and the women were stratified according to age (under 50 years, or 50 years or older) and use of tamoxifen (yes or no). All participants were then randomly assigned in a double-blinded fashion to one of two groups: those receiving megestrol acetate (Megace) first (group 1), who received the drug for four weeks, followed by placebo for four weeks; or those receiving placebo first (group 2), who received placebo for four weeks, followed by megestrol acetate for four weeks.
After randomization, the patients were given a set of questionnaires and two coded, blister-packed medication cards containing an eight-week supply of study medication (20 mg of megestrol acetate or placebo twice daily) labeled with the days and weeks of the study. The patients were instructed not to take any tablets for the first seven days but to document the number and severity of their hot flashes each day on the questionnaire for the first week. For the subsequent eight weeks, they were to take one tablet twice each day, making sure that they were taking the medication for the correct week on the medication card, and to record the number and severity of hot flashes each day on the questionnaire for the corresponding week. The patients were also instructed to record selected toxic effects (appetite changes, fluid retention, or vaginal problems) on a weekly basis. Every two weeks, the patients were either evaluated at the medical center or contacted by telephone by an oncology nurse, who documented compliance, encouraged completion of the questionnaires, and addressed any problems. When they had completed the double-blind medication, the patients were asked to indicate their preference for one study drug or the other on the last page of the questionnaire, then return their questionnaires and medication cards to the medical center.
After the ninth week, the medication code was broken and the patients were allowed to continue to take megestrol acetate in an open-label manner for four weeks, if they wished to do so. During the open-label period of the study, the daily dose of megestrol acetate was titrated from 10 to 80 mg per day, as necessary, to determine the lowest dose that effectively controlled hot flashes. During this titration phase, doses were not to be changed more often than once per week, and the patients were asked to record the number and severity of their hot flashes each day on the corresponding questionnaire for that week.
Statistical Analysis
Since this was a crossover study, the therapeutic effects of megestrol acetate and placebo could be compared in two ways for each measure of efficacy: patients could be used as their own controls in a standard crossover analysis, or alternatively, the values recorded in the first period for the patients taking each study drug could be compared and the second-period values ignored. Since there were substantial carryover effects when megestrol acetate was taken before placebo, the second analysis was more informative in this study. Nonparametric tests15 (Wilcoxon rank-sum, chi-square, and Fisher's exact tests) were used because of the skewed distributions of most of the data on efficacy and toxicity. All P values are two-tailed.
Three variables were used to assess the efficacy of treatment: the average number of hot flashes per day, the average daily hot-flash score during the last week of a given treatment period, and the patient's preference at the end of the study. The average number of hot flashes per day was adjusted by dividing this number by the average number of hot flashes per day at base line. The average daily hot-flash score for each patient was calculated by adding the total number of mild hot flashes plus twice the number of moderate hot flashes plus three times the number of severe hot flashes plus four times the number of very severe hot flashes recorded in a given week and then dividing the sum by the number of days (a minimum of four) on which values were recorded. The average daily hot-flash score was adjusted by dividing it by the average daily hot-flash score at base line.
Results
From May 8, 1992, through May 5, 1993, 100 women and 66 men were enrolled in the trial and randomly assigned to group 1 (megestrol acetate first) or group 2 (placebo first). One woman withdrew from the study before starting any medication, and two women were ineligible. The two groups were well balanced with respect to the stratification factors (Table 1Table 1
Characteristics of 97 Women and 66 Men Receiving Megestrol Acetate or Placebo for Hot Flashes.). All 163 patients who could be evaluated provided information for the analysis of toxicity. Approximately 82 percent of the women and 91 percent of the men provided usable data for the analysis of efficacy.During the base-line week, the median number of hot flashes per day was 6.1 (range, 0.9 to 21.4) for the women and 8.4 (range, 2.0 to 29.1) for the men; the median hot-flash score was 13.0 for the women and 17.0 for the men. There were no significant differences in base-line values between the study groups for either sex.
During the first four-week medication period, megestrol acetate significantly decreased the frequency of hot flashes and the hot-flash scores for both men and women (Table 2Table 2
Frequency and Severity of Hot Flashes during the Fourth Week of the First Treatment Period.). In group 2, there was a 21 percent reduction in the hot-flash score after four weeks of placebo, whereas in group 1, there was an 85 percent reduction in the hot-flash score after four weeks of megestrol acetate (P<0.001).Since 14 percent of the patients did not provide complete data for the above analyses, we used an intention-to-treat analysis to reexamine the data for all 163 eligible treated patients. We chose as an end point the percentage of patients who reported a 50 percent reduction in the daily frequency of hot flashes during the first treatment period, as compared with the base-line daily frequency. Seventy-one percent of the women in group 1 (34 of 48) reported a 50 percent reduction in hot flashes, as compared with 24 percent (12 of 49) in group 2 (P<0.001 by the Wilcoxon exact test). Seventy-nine percent of the men in group 1 (26 of 33) reported a 50 percent reduction in hot flashes, as compared with 12 percent (4 of 33) in group 2 (P<0.001 by the Wilcoxon exact test).
Figure 1Figure 1
Mean Hot-Flash Scores for Women (Panel A) and Men (Panel B) Receiving Megestrol Acetate or Placebo. shows the course of changes in the hot-flash score after the patients started taking megestrol acetate or placebo. It generally took two to three weeks of megestrol acetate therapy to achieve a maximal effect, and the hot flashes generally did not increase in frequency or severity until two to three weeks after the switch from megestrol acetate to placebo. Figure 1 also shows an unexpected finding: there appeared to be a substantial increase in the women's hot-flash scores for a few days after megestrol acetate was started. This increase occurred in both the women who received megestrol acetate as the initial study medication and those who received it after taking placebo for four weeks. The hot-flash scores did not increase after the women started taking the placebo, nor did the men's scores increase initially with megestrol acetate. After noting this phenomenon, we looked at the group of women who chose to receive open-label megestrol acetate after the double-blind study had been completed. These data, presented in Figure 2Figure 2Mean Hot-Flash Scores for Women during the Base-Line Week, the Two Four-Week Crossover Periods, and the Four-Week Period of Open-Label Megestrol Acetate., also show a spike in the severity of hot flashes for a few days after the reinitiation of megestrol acetate. With further examination, it became apparent that this temporary increase in the severity of hot flashes occurred only in the women who were concomitantly receiving tamoxifen.Exploratory analyses did not reveal any substantial differences in therapeutic effects between the two groups of patients, according to sex, age, base-line severity of hot flashes, duration of hot flashes, or use of tamoxifen (other than the temporary increase in the severity of hot flashes noted above).
The crossover analyses had to be ignored because of significantly different carryover effects, reflecting a persistent reduction in hot flashes during the placebo period in the patients who received megestrol acetate first (Figure 1).
Data on side effects were obtained from the weekly questionnaires that the patients completed. The patients were asked whether there had been any change in their appetite during the preceding week or whether they felt they had fluid retention; the women were also asked whether they had any vaginal symptoms, such as dryness, irritation, or discharge. There was no suggestion that megestrol acetate was related to any of these symptoms. We did not specifically inquire about other potential side effects, such as mood changes, migraine headaches, or vaginal bleeding, but we did include a general question about any side effects attributed to the study medication. The only evident toxic effect was vaginal bleeding, which was reported by 15 women (31 percent) who initially received megestrol acetate and had bleeding subsequently while receiving placebo. Vaginal bleeding was reported during the first week after discontinuation of megestrol acetate by 27 percent of the 15 women and during the second, third, and fourth weeks by 53, 13, and 6 percent, respectively. None of the women who initially received placebo reported vaginal bleeding.
On completion of the nine-week protocol, patients were asked which of the two four-week study medications worked better to reduce hot flashes. Of the 67 patients who initially received placebo and answered this question, 87 percent said megestrol acetate worked better, 4 percent said placebo worked better, and 9 percent had no preference (P<0.001). Of the 58 patients who initially received megestrol acetate and answered this question, 45 percent chose megestrol acetate, 40 percent chose placebo, and 16 percent had no preference (P = 0.67). The differences in these percentages were probably related to the delayed effect after the start of megestrol acetate and the prolonged (carryover) effect after its cessation (Figure 1).
Discussion
Our data show that megestrol acetate can markedly diminish hot flashes in both men and women, supporting the conclusions from an uncontrolled pilot trial of this drug9 and other studies involving related progestational agents3,10-14. The specific mechanism for the reduction in hot flashes is not well understood. Medroxyprogesterone acetate does not appear to cause any estrogenic effect on vaginal cells,14 suggesting that progestational hormones do not act by being converted into estrogenic compounds.
Much of the literature on progestational agents as therapy for menopausal symptoms has focused on medroxyprogesterone acetate10-14. This drug is similar to megestrol acetate, and the available data on the two drugs suggest that they have similar effects on hot flashes, although no direct comparison has been undertaken.
It may take two to three weeks before megestrol acetate begins to have a beneficial effect on hot flashes, and the effect may persist for weeks after discontinuation of the drug. This pattern is similar to that seen with estrogen-replacement therapy16. In addition, the effect of megestrol acetate on hot flashes in women (an 83 percent reduction in the hot-flash score) is remarkably similar to that reported with estrogen therapy (an 85 percent reduction in vasomotor hot flashes)16.
The increase in the hot-flash score during the first few days after the start of megestrol acetate treatment was a surprise, since we are unaware of any other report of this phenomenon. It appears to be a real finding rather than an artifact of the analysis, and it apparently occurs only in women taking tamoxifen. The cause of this initial agonist-like effect before a subsequent antagonist-like effect on hot flashes in women is not clear.
This study did not examine the possibility of long-term side effects. On the basis of data from studies using higher doses of megestrol acetate and studies examining the long-term use of low doses of estrogens and progesterone in healthy women, several theoretical side effects should be considered. These include weight gain, thromboembolic disorders, edema, lipid changes, cardiovascular morbidity, and the possible influence of megestrol acetate on bone structure and on hormonally sensitive cancers, such as breast, endometrial, and prostate tumors. In addition, male impotence has been reported with high doses of megestrol acetate,17 but this is not a problem in men who are receiving androgen-deprivation therapy.
On the basis of our data, appetite stimulation and weight gain would not be expected to be serious problems in most patients receiving low-dose megestrol acetate, since there was no suggestion of appetite stimulation with four weeks of therapy. Appetite stimulation with megestrol acetate is dose-dependent when the dose ranges from 160 to 800 mg per day,18 and we used a much lower dose to control hot flashes in our subjects.
To date, thromboembolic toxicity has not been clearly associated with large doses of megestrol acetate in placebo-controlled clinical trials19. Nonetheless, data from some studies suggest an increased risk of thromboembolic disease with high doses of megestrol acetate,19 and preliminary results from one of our placebo-controlled trials indicate an increased incidence of thromboembolic problems when a large dose of megestrol acetate (800 mg per day) is used in conjunction with combination chemotherapy in patients with advanced, incurable lung cancer (unpublished data). Thus, although there are no convincing data one way or the other, it is conceivable that the prolonged use of low doses of megestrol acetate may slightly increase the risk of thromboembolic disease in a manner similar to that suggested with oral contraceptives20-23. With hormone-replacement therapy, however, there is no clearly discerned relation between thromboembolic problems and treatment with estrogen and progesterone24.
The possible effects of low doses of megestrol acetate on the courses of hormonally sensitive tumors of the breast, endometrium, and prostate are unknown. Although it is possible to hypothesize that low doses of megestrol acetate may stimulate the growth of hormonally sensitive tumors in a manner similar to that of low doses of estrogen in breast and endometrial cancer and low doses of androgens in prostate cancer, it is also plausible that megestrol acetate can inhibit the growth of these cancers. Large doses of megestrol acetate have been reported to have antitumor activity in breast,25 endometrial,26 and prostate27 cancer. The influence of low doses of megestrol acetate on hormonal therapy with drugs such as tamoxifen is also unknown. Thus, at this time there is no substantial evidence to suggest that low doses of megestrol acetate will stimulate (or inhibit) the growth of tumors in humans or influence hormonal treatment with drugs such as tamoxifen, although the possibility of these effects should be the subject of future research.
The influence of low-dose megestrol acetate on cardiovascular disease has not been clarified, but concern has been expressed about the effect of progesterone on lipid levels28. Further data are needed to understand this effect. On a positive note, there are data suggesting that progestational agents can potentiate bone mineralization and thus provide protection against osteoporosis, although the definitive effect of progesterone on bones has not been clarified29,30.
In view of the results of this trial, two questions should be addressed: Are hot flashes a prominent enough symptom to require therapy in men who have undergone androgen-deprivation therapy or in women with breast cancer? If so, what treatment options are available for these patients?
Hot flashes have been reported to occur in over 75 percent of men who have undergone an orchiectomy and to interfere with their quality of life3. Androgens can abolish hot flashes in men,31 but their use would defeat the purpose of androgen-deprivation therapy. Estrogens may decrease hot flashes, but at the risk of gynecomastia, breast tenderness, and increased cardiovascular morbidity32. Cyproterone acetate, an antiandrogen with progestational properties, has been reported to decrease hot flashes after an orchiectomy,33 but this drug is not commercially available in the United States. This leaves megestrol acetate as the recommended treatment for hot flashes in patients with prostate cancer who have undergone androgen-deprivation therapy.
It is well known that hot flashes are a substantial clinical problem in menopausal women, whether or not they have a history of breast cancer. Estrogens are the mainstay of treatment for hot flashes in most menopausal women but have generally been contraindicated in those with a history of breast cancer. The wisdom behind this contraindication is currently a subject of considerable debate, especially in the case of women with small breast tumors and a very high probability of a cure with local therapy alone34. It has been suggested that estrogen treatment combined with tamoxifen is a rational approach,35 although this is not widely accepted. All in all, estrogens are not currently used in most patients with a history of breast cancer. Although several nonhormonal antidotes, such as clonidine, methyldopa, and belladonna alkaloids, have been proposed for treating menopausal hot flashes, none are very effective36-39. The data from our trial demonstrate that low doses of megestrol acetate can substantially attenuate hot flashes in most women, making this drug a reasonable treatment option for patients with breast cancer who have bothersome hot flashes.
Supported in part by grants (CA-25224, CA-37404, CA-15083, CA-35103, CA-37417, CA-35101, CA-35195, CA-35269, CA-35448, CA-35272, CA-52352, CA-35415, and CA-35113) from the National Cancer Institute.
Source Information
From the Departments of Oncology and Urology, Mayo Clinic and Mayo Foundation, Rochester, Minn. (C.L.L., S.K.Q., J.R.O., A.M.D., J.E.O.); Siouxland Hematology-Oncology Associates, Sioux City, Iowa (J.C.M.); the Carle Cancer Center Community Clinical Oncology Program, Urbana, Ill. (A.K.H.); the Sioux Community Cancer Consortium, Sioux Falls, S.D. (R.A.N.); the Quain and Ramstad Clinic, Bismarck, N.D. (T.F.); the St. Luke's Hospitals Community Clinical Oncology Program, Fargo, N.D. (C.J.); the Grand Forks Clinic, Grand Forks, N.D. (N.E.K.); the Iowa Oncology Research Association Community Clinical Oncology Program, Des Moines (W.W.B.); and the Nebraska Oncology Group, Creighton University and University of Nebraska Medical Center, Omaha (R.M.R.).
Address reprint requests to Dr. Loprinzi at the Mayo Clinic, 200 First St., SW, Rochester, MN 55905.
Additional participating investigators and institutions are listed in the Appendix.
Appendix
Additional institutions and investigators participating in the collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic include the Duluth Community Clinical Oncology Program, Duluth, Minn. (J.E. Krook); the Geisinger Clinical Oncology Program, Danville, Pa. (R.M. Goldberg); the Ochsner Community Clinical Oncology Program, New Orleans (C.G. Kardinal); the St. Cloud Clinic of Internal Medicine, St. Cloud, Minn. (H.E. Windschitl); the Cedar Rapids Oncology Project Community Clinical Oncology Program, Cedar Rapids, Iowa (M. Wiesenfeld); the Toledo Community Clinical Oncology Program, Toledo, Ohio (P.L. Schaefer); the Illinois Oncology Research Association Community Clinical Oncology Program, Peoria (J.B. Gerstner); and the Rapid City Regional Oncology Group, Rapid City, S.D. (L.P. Ebbert).
- References
References
1
Fisher B ,Costantino J ,Redmond C , et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484
Full Text | Web of Science | Medline2
Casper RF ,Yen SSC . Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312
CrossRef | Web of Science | Medline3
Charig CR ,Rundle JS . Flushing: long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989;33:175-178
CrossRef | Web of Science | Medline4
Frodin T ,Alund G ,Varenhorst E . Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 1985;7:203-208
CrossRef | Web of Science | Medline5
Steinfeld AD ,Reinhardt C . Male climacteric after orchiectomy in patient with prostatic cancer. Urology 1980;16:620-622
CrossRef | Web of Science | Medline6
McCallum KA ,Reading C . Hot flushes are induced by thermogenic stimuli. Br J Urol 1989;64:507-510
CrossRef | Medline7
Ginsburg J ,O'Reilly B . Climacteric flushing in a man. BMJ 1983;287:262-262
CrossRef | Web of Science | Medline8
Byar DP . The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-1130
CrossRef | Web of Science | Medline9
Erlik Y ,Meldrum DR ,Lagasse LD ,Judd HL . Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women. Maturitas 1981;3:167-172
CrossRef | Web of Science | Medline10
Bullock JL ,Massey FM ,Gambrell RD Jr . Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168
Web of Science | Medline11
Morrison JC ,Martin DC ,Blair RA , et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104
Web of Science | Medline12
Albrecht BH ,Schiff I ,Tulchinsky D ,Ryan KJ . Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631-635
Web of Science | Medline13
Young RL ,Kumar NS ,Goldzieher JW . Management of menopause when estrogen cannot be used. Drugs 1990;40:220-230
CrossRef | Web of Science | Medline14
Schiff I ,Tulchinsky D ,Cramer D ,Ryan KJ . Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445
CrossRef | Web of Science | Medline15
Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioral sciences. 2nd ed. New York: McGraw-Hill, 1988.
16
Haas S ,Walsh B ,Evans S ,Krache M ,Ravnikar V ,Schiff I . The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988;71:671-676
Web of Science | Medline17
Creagan ET ,Ingle JN ,Schutt AJ ,Schaid DJ . A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989;12:152-155
CrossRef | Web of Science | Medline18
Loprinzi CL ,Michalak JC ,Schaid DJ , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-767
Web of Science | Medline19
Loprinzi CL ,Johnson PA ,Jensen M . Megestrol acetate for anorexia and cachexia. Oncology 1992;49:Suppl 2:46-49
CrossRef | Web of Science | Medline20
Oral contraception and thrombo-embolic diseaseJ Coll Gen Pract 1967;13:267-279
21
Inman WHW ,Vessey MP . Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. BMJ 1968;2:193-199
CrossRef | Web of Science | Medline22
Vessey MP ,Doll R . Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 1969;2:651-657
CrossRef | Web of Science | Medline23
Sartwell PE ,Masi AT ,Arthes FG , et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969;90:365-380
Web of Science | Medline24
Gambrell RD Jr . The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982;37:457-474
Web of Science | Medline25
Benghiat A ,Cassidy SA ,Davidson HE ,Mancero FS ,Pickard JG ,Tyrrell CJ . Megestrol acetate in the treatment of advanced post-menopausal breast cancer. Eur J Surg Oncol 1986;12:43-45
Web of Science | Medline26
Wentz WB . Progestin therapy in lesions of the endometrium. Semin Oncol 1985;12:Suppl 1:23-27
Web of Science | Medline27
Bonomi P ,Pessis D ,Bunting N , et al. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol 1985;12:Suppl 1:36-39
Web of Science | Medline28
Mishell DR Jr, ed. Menopause: physiology and pharmacology. Chicago: Year Book Medical, 1987:199-200.
29
Tremollieres FA ,Strong DD ,Baylink DJ ,Mohan S . Progesterone and promegestone stimulate human bone cell proliferation insulin-like growth factor-2 production. Acta Endocrinol (Copenh) 1992;126:329-337
Medline30
Prior JC . Progesterone as a bone-trophic hormone. Endocr Rev 1990;11:386-398
CrossRef | Web of Science | Medline31
Feldman JM ,Postlethwaite RW ,Glenn JF . Hot flashes and sweats in men with testicular insufficiency. Arch Intern Med 1976;136:606-608
CrossRef | Web of Science | Medline32
Atala A ,Amin M ,Harty JI . Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology 1992;39:108-110
CrossRef | Web of Science | Medline33
Eaton AC ,McGuire N . Cyproterone acetate in treatment of post-orchidectomy hot flushes: double-blind cross-over trial. Lancet 1983;2:1336-1337
CrossRef | Web of Science | Medline34
Marchant DJ . Estrogen-replacement therapy after breast cancer: risks versus benefits. Cancer 1993;71:Suppl:2169-2176
CrossRef | Web of Science | Medline35
Powles TJ ,Tillyer CR ,Jones AL , et al. Prevention of breast cancer with tamoxifen -- an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990;26:680-684
CrossRef | Web of Science | Medline36
Goldberg RM ,Loprinzi CL ,O'Fallon JR , et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158
Web of Science | Medline37
Young RL ,Kumar NS ,Goldzieher JW . Management of menopause when estrogen cannot be used. Drugs 1990;40:220-230
CrossRef | Web of Science | Medline38
Bergmans MGM ,Merkus JMWM ,Corbey RS ,Schellekens LA ,Ubachs JM . Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-234
CrossRef | Web of Science | Medline39
Nesheim BI ,Saetre T . Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 1981;20:413-416
CrossRef | Web of Science | Medline
- Citing Articles (167)
Citing Articles
1
Jason M Jones, Manish Kohli, Charles L Loprinzi. (2012) Androgen deprivation therapy-associated vasomotor symptoms. Asian Journal of Andrology
CrossRef2
Grace W. Pien, Barbara A. Phillips, Nancy A. Collop. 2012. Sleep in Women. , 717-734.
CrossRef3
K. Haest, A. Kumar, B. Van Calster, K. Leunen, A. Smeets, F. Amant, P. Berteloot, H. Wildiers, R. Paridaens, E. Van Limbergen, C. Weltens, H. Janssen, S. Peeters, J. Menten, I. Vergote, B. Morlion, J. Verhaegen, M. R. Christiaens, P. Neven. (2011) Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Annals of Oncology
CrossRef4
Mathis Grossmann, Jeffrey D. Zajac. (2011) Management of Side Effects of Androgen Deprivation Therapy. Endocrinology & Metabolism Clinics of North America 40:3, 655-671
CrossRef5
Julie L. Otte, Janet S. Carpenter, Xin Zhong, Peter A. S. Johnstone. (2011) Feasibility Study of Acupuncture for Reducing Sleep Disturbances and Hot Flashes in Postmenopausal Breast Cancer Survivors. Clinical Nurse Specialist 25:5, 228-236
CrossRef6
Holly L. Thacker. (2011) Assessing Risks and Benefits of Nonhormonal Treatments for Vasomotor Symptoms in Perimenopausal and Postmenopausal Women. Journal of Women's Health 20:7, 1007-1016
CrossRef7
Deirdre R. Pachman, Debra Barton, Paul E. Carns, Paul J. Novotny, Sherry Wolf, Breanna Linquist, Sadhna Kohli, DeAnne R. Smith, Charles L. Loprinzi. (2011) Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Supportive Care in Cancer 19:7, 941-947
CrossRef8
Bassam Estfan. (2011) Essential Drugs in Supportive Care. Seminars in Oncology 38:3, 413-423
CrossRef9
Katrien Vandecasteele, Piet Ost, Willem Oosterlinck, Valérie Fonteyne, Wilfried De Neve, Gert De Meerleer. (2011) Evaluation of the Efficacy and Safety of Salvia officinalis in Controlling Hot Flashes in Prostate Cancer Patients Treated with Androgen Deprivation. Phytotherapy Researchn/a-n/a
CrossRef10
Raymond E. Bourey. (2011) Primary Menopausal Insomnia: Definition, Review, and Practical Approach. Endocrine Practice 17:1, 122-131
CrossRef11
Gary R Elkins, William I Fisher, Aimee K Johnson. (2011) Hypnosis for hot flashes among postmenopausal women study: A study protocol of an ongoing randomized clinical trial. BMC Complementary and Alternative Medicine 11:1, 92
CrossRef12
Julie Eve Desmarais, Karl J. Looper. (2010) Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions. Maturitas 67:4, 296-308
CrossRef13
Tomasz M. Beer, Maria Benavides, Sandra L. Emmons, Margaret Hayes, Guohui Liu, Mark Garzotto, Deirdre Donovan, Nina Katovic, Caron Reeder, Kristine Eilers. (2010) Acupuncture for Hot Flashes in Patients With Prostate Cancer. Urology 76:5, 1182-1188
CrossRef14
Matti S. Aapro. (2010) Challenges in Clinical Patient Management. Cancer Investigation 28:Supplement 1, 14-27
CrossRef15
Wolfgang Janni, Philip Hepp. (2010) Adjuvant aromatase inhibitor therapy: Outcomes and safety. Cancer Treatment Reviews 36:3, 249-261
CrossRef16
G. W. M. Millington, R. A. C. Graham-Brown. 2010. Skin and Skin Disease Throughout Life. , 1-29.
CrossRef17
Jacques Irani, Laurent Salomon, Rostand Oba, Philippe Bouchard, Nicolas Mottet. (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. The Lancet Oncology 11:2, 147-154
CrossRef18
Charles L Loprinzi, Sherry L Wolf. (2010) Hot flushes: mostly sex neutral?. The Lancet Oncology 11:2, 107-108
CrossRef19
Jessica Frisk. (2010) Managing hot flushes in men after prostate cancer—A systematic review. Maturitas 65:1, 15-22
CrossRef20
Rachel Michaelson-Cohen, Uziel Beller. (2009) Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology 21:5, 407-411
CrossRef21
Debra L. Barton, Charles L. Loprinzi. (2009) Does hormonal therapy decrease tamoxifen associated hot flashes?. Breast Cancer Research and Treatment 116:3, 529-530
CrossRef22
Charles L. Loprinzi, Debra L. Barton. (2009) On hot flash mechanism, measurement, and treatment. Menopause 16:4, 621-623
CrossRef23
Supriya G. Mohile, Karen Mustian, Kathryn Bylow, William Hall, William Dale. (2009) Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology 70:3, 235-255
CrossRef24
Ciska Buijs, Constantijne H. Mom, Pax H. B. Willemse, H. Marike Boezen, J. Marina Maurer, A. N. Machteld Wymenga, Robert S. Jong, Peter Nieboer, Elisabeth G. E. Vries, Marian J. E. Mourits. (2009) Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Research and Treatment 115:3, 573-580
CrossRef25
Anita Schwandt, Jorge A Garcia. (2009) Complications of androgen deprivation therapy in prostate cancer. Current Opinion in Urology 19:3, 322-326
CrossRef26
Aditya Bardia, Paul Novotny, Jeff Sloan, Deb Barton, Charles Loprinzi. (2009) Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use. Menopause 16:3, 477-483
CrossRef27
Hideki Sakai, Tsukasa Igawa, Toshifumi Tsurusaki, Morishi Yura, Yasuyuki Kusaba, Mikio Hayashi, Shotaro Iwasaki, Hironobu Hakariya, Tanetoshi Hara, Hiroshi Kanetake. (2009) Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer. Urology 73:3, 635-640
CrossRef28
Margaret Rees. (2009) Alternative treatments for the menopause. Best Practice & Research Clinical Obstetrics & Gynaecology 23:1, 151-161
CrossRef29
M. Hickey, M. Peate, C.M. Saunders, M. Friedlander. (2009) Breast cancer in young women and its impact on reproductive function. Human Reproduction Update 15:3, 323-339
CrossRef30
Jessica Frisk, Anna-Clara Spetz, Hans Hjertberg, Bill Petersson, Mats Hammar. (2009) Two Modes of Acupuncture as a Treatment for Hot Flushes in Men with Prostate Cancer—A Prospective Multicenter Study with Long-Term Follow-Up. European Urology 55:1, 156-163
CrossRef31
V. Stearns. (2009) Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626. Breast Diseases: A Year Book Quarterly 20:2, 211-212
CrossRef32
Charles L. Loprinzi, Debra L. Barton, Jeff A. Sloan, Paul J. Novotny, Sherry Wolf. (2009) Newer antidepressants for hot flashes-should their efficacy still be up for debate?. Menopause 16:1, 184-187
CrossRef33
Dawn L. Hershman, Christina Cho, Katherine D. Crew. (2009) Management of complications from estrogen deprivation in breast cancer patients. Current Oncology Reports 11:1, 29-36
CrossRef34
Nancy E. Avis, Claudine Legault, Remy R. Coeytaux, May Pian-Smith, Jan L. Shifren, Wunian Chen, Peter Valaskatgis. (2008) A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. Menopause 15:6, 1070-1078
CrossRef35
Rahim Moineddin, Debra A. Butt, George Tomlinson, Joseph Beyene. (2008) Identifying subpopulations for subgroup analysis in a longitudinal clinical trial. Contemporary Clinical Trials 29:6, 817-822
CrossRef36
Thomas W Flaig, L Michael Glodé. (2008) Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opinion on Pharmacotherapy 9:16, 2829-2841
CrossRef37
J. Irani. (2008) Prise en charge des effets secondaires de l’hormonoprivation androgénique. Oncologie 10:11, 661-665
CrossRef38
C. L. Loprinzi, A. C. Dueck, B. S. Khoyratty, D. L. Barton, S. Jafar, K. M. Rowland, P. J. Atherton, G. W. Marsa, W. H. Knutson, J. D. Bearden, L. Kottschade, T. R. Fitch. (2008) A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Annals of Oncology 20:3, 542-549
CrossRef39
Axel Grothey, Alex A. Adjei, Steve R. Alberts, Edith A. Perez, Kurt A. Jaeckle, Charles L. Loprinzi, Daniel J. Sargent, Jeff A. Sloan, Jan C. Buckner. (2008) North Central Cancer Treatment Group—Achievements and Perspectives. Seminars in Oncology 35:5, 530-544
CrossRef40
Charles L Loprinzi, Sherry L Wolf, Debra L Barton, Nadia NI Laack. (2008) Symptom management in premenopausal patients with breast cancer. The Lancet Oncology 9:10, 993-1001
CrossRef41
C Falci, A Brunello, U Basso, A Roma, S Monfardini. (2008) Medical approach to advanced prostate cancer in older patients. Aging Health 4:5, 481-494
CrossRef42
Charles L. Loprinzi, Debra L. Barton, Jeff A. Sloan, Paul J. Novotny, Shaker R. Dakhil, Joseph D. Verdirame, Wilma H. Knutson, Joseph Kelaghan, Brad Christensen. (2008) Mayo Clinic and North Central Cancer Treatment Group hot flash studies. Menopause 15:4, 655-660
CrossRef43
M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, V. Stearns. (2008) Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of Oncology 19:10, 1669-1680
CrossRef44
Joaquín Carballido, José Luis Tisaire, Núria Perulero. (2008) Desarrollo de un cuestionario sobre la repercusión de los sofocos en la calidad de vida de los pacientes con cáncer de próstata avanzado. Estudio ESCAPA. Medicina Clínica 130:15, 561-567
CrossRef45
Debra A. Butt, Michael Lock, Jacqueline E. Lewis, Sue Ross, Rahim Moineddin. (2008) Gabapentin for the treatment of menopausal hot flashes. Menopause 15:2, 310-318
CrossRef46
Eric A Singer, Dragan J Golijanin, Hiroshi Miyamoto, Edward M Messing. (2008) Androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy 9:2, 211-228
CrossRef47
Susan Thompson, Aditya Bardia, Angelina Tan, Debra L. Barton, Lisa Kottschade, Jeff A. Sloan, Brad Christensen, DeAnne Smith, Charles L. Loprinzi. (2008) Levetiracetam for the treatment of hot flashes: a phase II study. Supportive Care in Cancer 16:1, 75-82
CrossRef48
Preston C Sprenkle, Harry Fisch. (2007) Pathologic effects of testosterone deprivation. Current Opinion in Urology 17:6, 424-430
CrossRef49
Jeanne Leventhal Alexander, Henry Burger, Lorraine Dennerstein, Nancy Fugate Woods, Susan R Davis, Krista Kotz, Julie Van Winkle, Gregg Richardson, Anna Ratka, Bruce Kessel. (2007) Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. Expert Review of Neurotherapeutics 7:11s, S115-S137
CrossRef50
Nicoletta Biglia, Franziska Kubatzki, Paola Sgandurra, Riccardo Ponzone, Davide Marenco, Elisa Peano, Piero Sismondi. (2007) Mirtazapine for the Treatment of Hot Flushes in Breast Cancer Survivors: A Prospective Pilot Trial. The Breast Journal 13:5, 490-495
CrossRef51
Vered Stearns. (2007) Clinical update: new treatments for hot flushes. The Lancet 369:9579, 2062-2064
CrossRef52
Gary Elkins, Joel Marcus, Vered Stearns, M. Hasan Rajab. (2007) Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psycho-Oncology 16:5, 487-492
CrossRef53
Tracy Sexton, Jawaid Younus, Francisco Perera, Lyn Kligman, Michael Lock. (2007) Oxybutynin for refractory hot flashes in cancer patients. Menopause 14:3, 505-509
CrossRef54
Yael Nir, Mary I. Huang, Rosa Schnyer, Bertha Chen, Rachel Manber. (2007) Acupuncture for postmenopausal hot flashes. Maturitas 56:4, 383-395
CrossRef55
Carrie Tompkins Stricker. (2007) Endocrine Effects of Breast Cancer Treatment. Seminars in Oncology Nursing 23:1, 55-70
CrossRef56
Louise Bordeleau, Kathleen Pritchard, Pamela Goodwin, Charles Loprinzi. (2007) Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clinical Therapeutics 29:2, 230-241
CrossRef57
Ann Vincent, Debra L. Barton, Jayawant N. Mandrekar, Stephen S. Cha, Teresa Zais, Dietlind L. Wahner-Roedler, Marina A. Keppler, Mary Jo Kreitzer, Charles Loprinzi. (2007) Acupuncture for hot flashes. Menopause 14:1, 45-52
CrossRef58
Grady, Deborah, . (2006) Management of Menopausal Symptoms. New England Journal of Medicine 355:22, 2338-2347
Full Text59
M. Rees. (2006) Gynaecological oncology perspective on management of the menopause. European Journal of Surgical Oncology (EJSO) 32:8, 892-897
CrossRef60
Charles L. Loprinzi, Debra Barton, Teresa Rummans. (2006) Newer antidepressants inhibit hot flashes. Menopause 13:4, 546-548
CrossRef61
Domingo G. Pérez, Charles L. Loprinzi, Jeff Sloan, Paul Novotny, Debra Barton, Lisa Carpenter, Deanne Smith, Brad Christensen, Teresa Rummans. (2006) Pilot Evaluation of Bupropion for the Treatment of Hot Flashes. Journal of Palliative Medicine 9:3, 631-637
CrossRef62
Jeffrey M. Holzbeierlein. (2006) Managing Complications of Androgen Deprivation Therapy for Prostate Cancer. Urologic Clinics of North America 33:2, 181-190
CrossRef63
Giampiero Porzio, Federica Aielli, Lucilla Verna, Claudio Porto, Paolo Aloisi, Katia Cannita, Enrico Ricevuto, Paolo Marchetti, Corrado Ficorella. (2006) Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. Supportive Care in Cancer 14:4, 389-391
CrossRef64
Gretchen G. Kimmick, James Lovato, Richard McQuellon, Emily Robinson, Hyman B. Muss. (2006) Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen. The Breast Journal 12:2, 114-122
CrossRef65
Constantijne H. Mom, Ciska Buijs, Pax H.B. Willemse, Marian J.E. Mourits, Elisabeth G.E. de Vries. (2006) Hot flushes in breast cancer patients. Critical Reviews in Oncology/Hematology 57:1, 63-77
CrossRef66
Pamela Atherton, Paul Novotny. (2005) Combining Information Across Symptom Studies. Current Problems in Cancer 29:6, 285-295
CrossRef67
Charles L. Loprinzi, Patrick J. Flynn, Lisa A. Carpenter, Pam Atherton, Debra L. Barton, Tait D. Shanafelt, Teresa A. Rummans, Jeff A. Sloan, Alex A. Adjei, Betty A. Mincey, Tom R. Fitch, Mary Collins. (2005) Pilot Evaluation of Citalopram for the Treatment of Hot Flashes in Women with Inadequate Benefit from Venlafaxine. Journal of Palliative Medicine 8:5, 924-930
CrossRef68
M. C. Gainford, C. Simmons, H. Nguyen, S. Verma, M. Clemons. (2005) A practical guide to the management of menopausal symptoms in breast cancer patients. Supportive Care in Cancer 13:8, 573-578
CrossRef69
PETER LANGENSTROER, BRANDON KRAMER, BRADLEY CUTTING, CHRIS AMLING, THOMAS POULTAN, RAYMOND LANCE, J. BRANTLEY THRASHER. (2005) PARENTERAL MEDROXYPROGESTERONE FOR THE MANAGEMENT OF LUTEINIZING HORMONE RELEASING HORMONE INDUCED HOT FLASHES IN MEN WITH ADVANCED PROSTATE CANCER. The Journal of Urology 174:2, 642-645
CrossRef70
Ravi J. Kumar, Al Barqawi, E. David Crawford. (2005) Preventing and treating the complications of hormone therapy. Current Urology Reports 6:3, 217-223
CrossRef71
Kerin B Adelson, Charles L Loprinzi, Dawn L Hershman. (2005) Treatment of hot flushes in breast and prostate cancer. Expert Opinion on Pharmacotherapy 6:7, 1095-1106
CrossRef72
Allen C. Chen, Daniel P. Petrylak. (2005) Complications of androgen-deprivation therapy in men with prostate cancer. Current Urology Reports 6:3, 210-216
CrossRef73
Julian R Molina, Debra L Barton, Charles L Loprinzi. (2005) Chemotherapy-Induced Ovarian Failure. Drug Safety 28:5, 401-416
CrossRef74
Rodney Baber, Martha Hickey, Michelle Kwik. (2005) Therapy for Menopausal Symptoms During and After Treatment for Breast Cancer. Drug Safety 28:12, 1085-1100
CrossRef75
Michele L. Evans, Elizabeth Pritts, Eric Vittinghoff, Karen McClish, Kevin S. Morgan, Robert B. Jaffe. (2005) Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial. Obstetrics & Gynecology 105:1, 161-166
CrossRef76
Karen E. Moe. (2004) Hot flashes and sleep in women. Sleep Medicine Reviews 8:6, 487-497
CrossRef77
Myra S Hunter, Elizabeth A Grunfeld, Sangeeta Mittal, Pooja Sikka, Amanda-Jane Ramirez, Ian Fentiman, Hisham Hamed. (2004) Menopausal symptoms in women with breast cancer: Prevalence and treatment preferences. Psycho-Oncology 13:11, 769-778
CrossRef78
Sara Mobasseri, Philip R. Liebson, Lloyd W. Klein. (2004) Hormone Therapy and Selective Estrogen Receptor Modulators for Prevention of Coronary Heart Disease in Postmenopausal Women. Cardiology in Review 12:6, 287-298
CrossRef79
Mitsutoshi Yuzurihara, Yasushi Ikarashi, Masamichi Noguchi, Yoshio Kase, Shuichi Takeda, Masaki Aburada. (2004) Prevention by 17β-estradiol and progesterone of calcitonin gene-related peptide-induced elevation of skin temperature in castrated male rats. Urology 64:5, 1042-1047
CrossRef80
C. L. Loprinzi, D. L. Barton, L. A. Carpenter, J. A. Sloan, P. J. Novotny, M. T. Gettman, B. J. Christensen. (2004) Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men. Mayo Clinic Proceedings 79:10, 1247-1251
CrossRef81
TSUTOMU NISHIYAMA, SAORI KANAZAWA, REIKO WATANABE, MASAHIRO TERUNUMA, KOTA TAKAHASHI. (2004) Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. International Journal of Urology 11:9, 735-741
CrossRef82
N.J. Bundred, L.E. Turner. (2004) Postmenopausal hormone therapy before and after breast cancer: clinical experiences. Maturitas 49:1, S22-S31
CrossRef83
Edgar D Staren, Shuab Omer. (2004) Hormone replacement therapy in postmenopausal women. The American Journal of Surgery 188:2, 136-149
CrossRef84
Vered Stearns. (2004) Management of hot flashes in breast cancer survivors and men with prostate cancer. Current Oncology Reports 6:4, 285-290
CrossRef85
Nicoletta Biglia, Angelo Gadducci, Riccardo Ponzone, Riccardo Roagna, Piero Sismondi. (2004) Hormone replacement therapy in cancer survivors. Maturitas 48:4, 333-346
CrossRef86
Gary Elkins, Joel Marcus, Lynne Palamara, Vered Stearns. (2004) Can Hypnosis Reduce Hot Flashes in Breast Cancer Survivors? A Literature Review. American Journal of Clinical Hypnosis 47:1, 29-42
CrossRef87
Vittorio Unfer, Maria Luisa Casini, Loredana Costabile, Marcella Mignosa, Sandro Gerli, Gian Carlo Di Renzo. (2004) Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertility and Sterility 82:1, 145-148
CrossRef88
Allen C. Chen, Daniel P. Petrylak. (2004) Complications of androgen deprivation therapy in men with prostate cancer. Current Oncology Reports 6:3, 209-215
CrossRef89
Jeffrey M Holzbeierlein, Matthew D McLaughlin, J Brantley Thrasher. (2004) Complications of androgen deprivation therapy for prostate cancer. Current Opinion in Urology 14:3, 177-183
CrossRef90
T Elek, M Reich. (2004) Place des antidépresseurs sérotoninergiques dans la prise en charge des bouffées de chaleur en cancérologie. La Revue de Médecine Interne 25:3, 217-224
CrossRef91
Jo Marsden, Nigel Sacks. (2004) The Role of Hormone Replacement Therapy and Alternative Treatments. American Journal of Cancer 3:2, 67-78
CrossRef92
&NA;. (2004) Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society: Retracted. Menopause 11:1, 11-33
CrossRef93
Rowan T Chlebowski, Jung A Kim, Nananda F Col. (2003) Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Seminars in Oncology 30:6, 776-788
CrossRef94
J Dixon. (2003) Hormone replacement therapy and the breast. Surgical Oncology 12:4, 251-263
CrossRef95
Maria C. Graf, Pamela A. Geller. (2003) Treating Hot Flashes in Breast Cancer Survivors: A Review of Alternative Treatments to Hormone Replacement Therapy. Clinical Journal of Oncology Nursing 7:6, 637-640
CrossRef96
Nasser Mikhail. (2003) Lessons Learned from the Womenʼs Health Initiative Study. Southern Medical Journal 96:9, 940-941
CrossRef97
Daanish Hoda, Domingo G. Perez, Charles L. Loprinzi. (2003) Hot Flashes in Breast Cancer Survivors. The Breast Journal 9:5, 431-438
CrossRef98
H JOFFE, C SOARES, L COHEN. (2003) Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatric Clinics of North America 26:3, 563-580
CrossRef99
Jeanne Rozwadowski, Suzanne Brandenburg. (2003) Treatment of Menopausal Hot Flashes. Primary Care Case Reviews 6:2, 67-74
CrossRef100
Zbigniew Zylicz, Malgorzata Krajnik. (2003) Flushing and Sweating in an Advanced Breast Cancer Patient Relieved By Olanzapine. Journal of Pain and Symptom Management 25:6, 494-495
CrossRef101
Nicoletta Biglia, Marilena Cozzarella, Franca Cacciari, Riccardo Ponzone, Riccardo Roagna, Furio Maggiorotto, Piero Sismondi. (2003) Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 45:1, 29-38
CrossRef102
ME Del Giudice, CA Sawka, KI Pritchard, HA Llewellyn-Thomas, ME Trudeau, JE Lewis, E Franssen. (2003) Hormone Replacement Therapy after Treatment for Breast Cancer: Physicians' Attitudes towards Randomized Trials. Breast Cancer Research and Treatment 79:2, 213-223
CrossRef103
Paola Albertazzi, Mirella Bottazzi, David W. Purdie. (2003) Gabapentin for the management of hot flushes: a case series. Menopause 10:3, 214-217
CrossRef104
Jawaid Younus, Ian Simpson, Alison Collins, Xikui Wang. (2003) Mind control of menopause. Women's Health Issues 13:2, 74-78
CrossRef105
Gregory Zapantis, Nanette Santoro. (2003) The menopausal transition: characteristics and management. Best Practice & Research Clinical Endocrinology & Metabolism 17:1, 33-52
CrossRef106
P Kenemans, A Bosman. (2003) Breast cancer and post-menopausal hormone therapy. Best Practice & Research Clinical Endocrinology & Metabolism 17:1, 123-137
CrossRef107
Celestia S Higano. (2003) Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61:2, 32-38
CrossRef108
Mark Clemons, Andrew Clamp, Beverley Anderson. (2002) Management of the menopause in cancer survivors. Cancer Treatment Reviews 28:6, 321-333
CrossRef109
Debra Barton, Charles Loprinzi, Susan Quella, Jeff Sloan, Sandya Pruthi, Paul Novotny. (2002) Depomedroxyprogesterone Acetate for Hot Flashes. Journal of Pain and Symptom Management 24:6, 603-607
CrossRef110
Ebru Tarim, Tayfun Bagis, Esra Kilicdag, Serkan Erkanli, Erdogan Aslan, Esra Kuscu. (2002) Moclobemide in the treatment of hot flashes in postmenopausal women. Advances in Therapy 19:6, 258-265
CrossRef111
T. D. Shanafelt, D. L. Barton, A. A. Adjei, C. L. Loprinzi. (2002) Pathophysiology and Treatment of Hot Flashes. Mayo Clinic Proceedings 77:11, 1207-1218
CrossRef112
A KAUNITZ. (2002) Gynecologic problems of the perimenopause: evaluation and treatment. Obstetrics and Gynecology Clinics of North America 29:3, 455-473
CrossRef113
Patricia F. Harris, Patrick L. Remington, Amy Trentham-Dietz, Catherine I. Allen, Polly A. Newcomb. (2002) Prevalence and Treatment of Menopausal Symptoms Among Breast Cancer Survivors. Journal of Pain and Symptom Management 23:6, 501-509
CrossRef114
Donna S Zhukovsky. (2002) Fever and sweats in the patient with advanced cancer. Hematology/Oncology Clinics of North America 16:3, 579-588
CrossRef115
G. Bertelli. (2002) Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Annals of Oncology 13:6, 883-888
CrossRef116
Vered Stearns, Daniel F. Hayes. (2002) Approach to menopausal symptoms in women with breast cancer. Current Treatment Options in Oncology 3:2, 179-190
CrossRef117
Adolf E. Schindler. (2002) Hormone replacement therapy (HRT) in women after genital cancer. Maturitas 41, 105-111
CrossRef118
Michael A Weitzner, Joanne Moncello, Paul B Jacobsen, Susan Minton. (2002) A Pilot Trial of Paroxetine for the Treatment of Hot Flashes and Associated Symptoms in Women with Breast Cancer. Journal of Pain and Symptom Management 23:4, 337-345
CrossRef119
Mark A Moyad. (2002) Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 59:4, 20-33
CrossRef120
C. Kouriefs, M. Georgiou, R. Ravi. (2002) Hot flushes and prostate cancer: pathogenesis and treatment. BJU International 89:4, 379-383
CrossRef121
Mark A Moyad. (2002) The placebo effect and randomized trials: analysis of alternative medicine. Urologic Clinics of North America 29:1, 135-155
CrossRef122
Mark A Moyad. (2002) The placebo effect and randomized trials: analysis of conventional medicine. Urologic Clinics of North America 29:1, 125-133
CrossRef123
A. Albert, C. Altabre, F. Baró, E. Buendía, A. Cabero, M.J. Cancelo, C. Castelo-Branco, P. Chantre, M. Duran, J. Haya, P. Imbert, D. Juliá, J.L. Lanchares, P. Llaneza, M. Manubens, A. Miñano, F. Quereda, C. Ribes, F. Vázquez. (2002) Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: A multicentric, open, prospective and non-randomized trial. Phytomedicine 9:2, 85-92
CrossRef124
C. Pélissier, M. Maroni, H. Yaneva, S. Brin, F. Peltier-Pujol, M. Jondet. (2001) Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 40:1, 85-94
CrossRef125
Wood, Alastair J.J., , Shapiro, Charles L., Recht, Abram, . (2001) Side Effects of Adjuvant Treatment of Breast Cancer. New England Journal of Medicine 344:26, 1997-2008
Full Text126
A.Y. Rostom. (2001) The Management of Menopausal Sequelae in Patients with Breast Cancer. Clinical Oncology 13:3, 174-180
CrossRef127
Matthew R. Smith. (2001) COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR ADVANCED PROSTATE CANCER. Hematology/Oncology Clinics of North America 15:3, 559-571
CrossRef128
Charles L Loprinzi, Debra L Barton, Deb Rhodes. (2001) Management of hot flashes in breast-cancer survivors. The Lancet Oncology 2:4, 199-204
CrossRef129
Melvin J Silverstein, Steve Parker, James C Grotting, Richard J Cote, Christy A Russell. (2001) Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies11No competing interests declared.. Journal of the American College of Surgeons 192:2, 196-214
CrossRef130
Debra Barton, Charles Loprinzi, Dietlind Wahner-Roedler. (2001) Hot Flashes. Drugs & Aging 18:8, 597-606
CrossRef131
Kathryn A. Martin. (2000) Controversies in postmenopausal hormone replacement. Current Opinion in Endocrinology & Diabetes 7:6, 325-331
CrossRef132
Charles L Loprinzi, John W Kugler, Jeff A Sloan, James A Mailliard, Beth I LaVasseur, Debra L Barton, Paul J Novotny, Shaker R Dakhil, Kate Rodger, Teresa A Rummans, Bradley J Christensen. (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. The Lancet 356:9247, 2059-2063
CrossRef133
David H Barlow. (2000) Venlafaxine for hot flushes. The Lancet 356:9247, 2025-2026
CrossRef134
Leon Speroff, James Symons, Nona Kempfert, Jean Rowan. (2000) The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt??) on the frequency and intensity of vasomotor symptoms. Menopause 7:6, 383-390
CrossRef135
Burstein, Harold J., Winer, Eric P., . (2000) Primary Care for Survivors of Breast Cancer. New England Journal of Medicine 343:15, 1086-1094
Full Text136
Hemmie H.G Berendsen. (2000) The role of serotonin in hot flushes. Maturitas 36:3, 155-164
CrossRef137
Jo Marsden. (2000) Hormone replacement therapy and breast cancer. Maturitas 34, S11-S24
CrossRef138
E. Farish, J. F. Barnes, F. O'donoghue, C. D. Fletcher, K. Ekevall, D. M. Hart. (2000) The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 3:2, 125-134
CrossRef139
Tsunefumi Kobayashi, Mizuho Tamura, Minoru Hayashi, Yasuhiro Itano, Hirofumi Tanabe, Yasuhiro Katsuura, Tomohiro Ohta, Keiji Komoriya. (2000) Effects of Progesterone on the Elevation of Tail Skin Temperature in Ovariectomized Rats.. The Japanese Journal of Physiology 50:6, 651-656
CrossRef140
Glenn S Gerber, Gregory P Zagaja, Paul S Ray, Daniel B Rukstalis. (2000) Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55:1, 97-101
CrossRef141
Jerome P Richie. (1999) Anti-androgens and other hormonal therapies for prostate cancer. Urology 54:6, 15-18
CrossRef142
Shakuntala Kothari, Holly L. Thacker. (1999) RISK ASSESSMENT OF THE MENOPAUSAL PATIENT. Medical Clinics of North America 83:6, 1489-1502
CrossRef143
SUSAN K. QUELLA, CHARLES L. LOPRINZI, JEFF SLOAN, PAUL NOVOTNY, EDITH A. PEREZ, PATRICK A. BURCH, STANLEY J. ANTOLAK, THOMAS M. PISANSKY. (1999) PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER. The Journal of Urology 162:1, 98-102
CrossRef144
M Seifert, A Galid, E Kubista. (1999) Estrogen replacement therapy in women with a history of breast cancer. Maturitas 32:2, 63-68
CrossRef145
Esther Muscari Lin, Jennifer L. Aikin, Barbara C. Good. (1999) Premature Menopause After Cancer Treatment. Cancer Practice 7:3, 114-121
CrossRef146
Gaye McPhail. (1999) Menopause as an issue for women with breast cancer. Cancer Nursing 22:2, 164-171
CrossRef147
DAVID J. FARRAR. (1999) Megestrol Acetate: Promises and Pitfalls. AIDS Patient Care and STDs 13:3, 149-152
CrossRef148
Gail A Greendale, Nancy P Lee, Edga R Arriola. (1999) The menopause. The Lancet 353:9152, 571-580
CrossRef149
Beth Leedham, Patricia A. Ganz. (1999) Psychosocial Concerns and Quality of Life in Breast Cancer Survivors. Cancer Investigation 17:5, 342-348
CrossRef150
Janet S. Carpenter, Michael A. Andrykowski, Robert R. Freedman, Rita Munn. (1999) Feasibility and Psychometrics of an Ambulatory Hot Flash Monitoring Device. Menopause 6:3, 209-215
CrossRef151
Gwen Finck, Debra L Barton, Charles L Loprinzi, Susan K Quella, Jeff A Sloan. (1998) Definitions of Hot Flashes in Breast Cancer Survivors. Journal of Pain and Symptom Management 16:5, 327-333
CrossRef152
WILLIAM K. OH, PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. The Journal of Urology 160:4, 1220-1229
CrossRef153
WILLIAM K. OH, PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. The Journal of Urology1220-1229
CrossRef154
Janet S. Carpenter, Michael A. Andrykowski, Matthew Cordova, Lauren Cunningham, Jamie Studts, Patrick McGrath, Daniel Kenady, David Sloan, Rita Munn. (1998) Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 82:9, 1682-1691
CrossRef155
Susan K. Quella, Charles L. Loprinzi, Jeff A. Sloan, Nancy L. Vaught, Wanda L. DeKrey, Tammy Fischer, Gwen Finck, Nancy Pierson, Thomas Pisansky. (1998) Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82:9, 1784-1788
CrossRef156
Andrew J. Roth, Howard I. Scher. (1998) Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psycho-Oncology 7:2, 129-132
CrossRef157
R. J. Santen. (1998) Treatment of estrogen deficiency symptoms in women surviving breast cancer. Climacteric 1:2, 148-158
CrossRef158
Janie D Hirata, Lillian M Swiersz, Bonnie Zell, Rebecca Small, Bruce Ettinger. (1997) Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertility and Sterility 68:6, 981-986
CrossRef159
Roohollah Sharifi, Chirasakdi Ratanawong, Ashley Jung, Zhi Wu, Robert Browneller, Mary Lee. (1997) Therapeutic effects of leuprorelin microspheres in prostate cancer. Advanced Drug Delivery Reviews 28:1, 121-138
CrossRef160
Susan L. Hendrix. (1997) NONESTROGEN MANAGEMENT OF MENOPAUSAL SYMPTOMS. Endocrinology & Metabolism Clinics of North America 26:2, 379-390
CrossRef161
S. Bruce Malkowicz. (1996) SERUM PROSTATE-SPECIFIC ANTIGEN ELEVATION IN THE POST–RADICAL PROSTATECTOMY PATIENT. Urologic Clinics of North America 23:4, 665-675
CrossRef162
S.J. Gibbs, P.N. Plowman. (1996) Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Clinical Oncology 8:6, 346-352
CrossRef163
R. Lee Cox, E. David Crawford. (1995) Estrogens in the Treatment of Prostate Cancer. The Journal of Urology1991-1998
CrossRef164
R. Lee Cox, E. David Crawford. (1995) Estrogens in the Treatment of Prostate Cancer. The Journal of Urology 154:6, 1991-1998
CrossRef165
B. G. Wren. (1995) The management of urogenital atrophy following genital tract cancer. International Urogynecology Journal and Pelvic Floor Dysfunction 6:2, 61-62
CrossRef166
(1995) Megestrol Acetate for the Prevention of Hot Flashes. New England Journal of Medicine 332:1, 64-64
Full Text167
Charles L Loprinzi, Prema P. Peethambaram. (1995) Management of Menopausal Symptoms in Breast Cancer Patients. Annals of Medicine 27:6, 653-656
CrossRef
- Letters
